Lisata Therapeutics Files Q2 2024 10-Q
Ticker: LSTA · Form: 10-Q · Filed: Aug 12, 2024 · CIK: 320017
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Lisata's Q2 10-Q is in. Check financials and ops updates.
AI Summary
Lisata Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operations. Key financial figures and operational highlights are detailed within the filing.
Why It Matters
This filing provides investors with the latest financial performance and operational status of Lisata Therapeutics, crucial for understanding the company's trajectory in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — As a clinical-stage biopharmaceutical company, Lisata Therapeutics faces inherent risks related to drug development, regulatory approvals, and market adoption.
Key Players & Entities
- LISATA THERAPEUTICS, INC. (company) — Filer
- 0000320017-24-000051 (other) — Accession Number
- 20240630 (date) — Period of Report
- 20240812 (date) — Filed as of Date
- CALADRIUS BIOSCIENCES, INC. (company) — Former Company Name
- NeoStem, Inc. (company) — Former Company Name
- 2834 (other) — Standard Industrial Classification Code
- 222343568 (other) — IRS Number
- DE (other) — State of Incorporation
- 1231 (date) — Fiscal Year End
FAQ
What was Lisata Therapeutics' former company name?
Lisata Therapeutics, Inc. was formerly known as CALADRIUS BIOSCIENCES, INC. and before that, Caladrius Biosciences, Inc. and NeoStem, Inc.
What is Lisata Therapeutics' Standard Industrial Classification code?
Lisata Therapeutics' Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
In which state is Lisata Therapeutics incorporated?
Lisata Therapeutics is incorporated in Delaware (DE).
What is the business address of Lisata Therapeutics?
The business address of Lisata Therapeutics is 110 Allen Road, Second Floor, Basking Ridge, NJ 07920.
What is the SEC file number for Lisata Therapeutics?
The SEC file number for Lisata Therapeutics is 001-33650.
Filing Stats: 4,695 words · 19 min read · ~16 pages · Grade level 18 · Accepted 2024-08-12 16:21:38
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share LSTA The Nasdaq Capital Marke
Filing Documents
- lsta-20240630.htm (10-Q) — 930KB
- lsta-ex311_20240630.htm (EX-31.1) — 9KB
- lsta-ex312_20240630.htm (EX-31.2) — 9KB
- lsta-ex321_20240630.htm (EX-32.1) — 7KB
- lsta-ex322_20240630.htm (EX-32.2) — 7KB
- lsta-20240630_g1.jpg (GRAPHIC) — 178KB
- 0000320017-24-000051.txt ( ) — 6401KB
- lsta-20240630.xsd (EX-101.SCH) — 45KB
- lsta-20240630_cal.xml (EX-101.CAL) — 58KB
- lsta-20240630_def.xml (EX-101.DEF) — 175KB
- lsta-20240630_lab.xml (EX-101.LAB) — 625KB
- lsta-20240630_pre.xml (EX-101.PRE) — 418KB
- lsta-20240630_htm.xml (XML) — 727KB
- FINANCIAL INFORMATION
PART I- FINANCIAL INFORMATION Page No. Item 1.
Financial Statements
Financial Statements: 5 Consolidated Balance Sheets at June , 30 2024 (unaudited) and December 31, 2023 5 Consolidated Statements of Operations for the three and six months ended June 30 , 2024 and 2023 (unaudited) 6 Consolidated Statements of Comprehensive Loss for the three and si x months ended June 30 , 2024 and 2023 (unaudited) 7 Consolidated Statements of Equity for the three and six months ended June 30 , 2024 and 2023 (unaudited) 8 Consolidated Statements of Cash Flows for the six months ended June 3 0 , 2024 and 2023 (unaudited) 10 Notes to Unaudited Consolidated Financial Statements 11 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 31 Item 4.
Controls and Procedures
Controls and Procedures 31
- OTHER INFORMATION
PART II- OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 33 Item 1A.
Risk Factors
Risk Factors 33 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 33 Item 3. Defaults Upon Senior Securities 33 Item 4. Mine Safety Disclosures 33 Item 5. Other Information 33 Item 6. Exhibits 33
Signatures
Signatures 34 4 Index
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION
FINANCIAL STATEMENTS
ITEM 1. FINANCIAL STATEMENTS LISATA THERAPEUTICS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (In thousands, except share data) June 30, 2024 December 31, 2023 ASSETS (Unaudited) Cash and cash equivalents $ 28,293 $ 22,593 Marketable securities 9,969 27,942 Prepaid and other current assets 3,716 3,389 Total current assets 41,978 53,924 Property and equipment, net 119 175 Acquired license - intangible, net 228 263 Other assets 246 332 Total assets $ 42,571 $ 54,694 LIABILITIES, NON-CONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY Liabilities Accounts payable $ 728 $ 2,421 Accrued liabilities 3,729 4,169 Total current liabilities 4,457 6,590 Other long-term liabilities 119 210 Total liabilities 4,576 6,800 Commitments and Contingencies (Note 13) Stockholders' Equity Common stock, $ 0.001 par value, authorized 500,000,000 shares; issued 8,321,799 and 8,150,635 shares at June 30, 2024 and December 31, 2023, respectively; and outstanding, 8,321,061 and 8,149,897 shares at June 30, 2024 and December 31, 2023, respectively 8 8 Additional paid-in capital 577,552 576,971 Treasury stock, at cost; 738 shares at June 30, 2024 and December 31, 2023 ( 708 ) ( 708 ) Accumulated deficit ( 538,526 ) ( 528,081 ) Accumulated other comprehensive loss ( 77 ) ( 42 ) Total Lisata Therapeutics, Inc. stockholders' equity 38,249 48,148 Non-controlling interests ( 254 ) ( 254 ) Total equity 37,995 47,894 Total liabilities, non-controlling interests and stockholders' equity $ 42,571 $ 54,694 See accompanying notes to consolidated financial statements. 5 Index LISATA THERAPEUTICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share data) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Operating Expenses: Research and development $ 2,601 $ 3,162 $ 5,842 $ 6,341 General and administrative 2,922 3,713 6,282 7,378 Total operating expenses 5,523 6,875 12,124